U.S. Pharmaceutical representative fainted behind President Donald Trump during a White House announcement on a new deal to cut prices for weight-loss drugs.
United States Pharmaceutical executive collapsed in the Oval Office on Thursday November 6, 2025, during a televised event where President Donald Trump unveiled a new federal deal to make weight-loss medications more affordable.
The incident occurred as the President stood alongside top administration officials, including Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services. The man, identified by reporters as a Pharmaceutical Representative, suddenly lost his balance while standing directly behind Trump.
Footage from the event showed Dr. Oz rushing forward to support the man before he hit the ground. Attendees quickly surrounded the executive as reporters were escorted from the room. Witnesses said officials elevated the man’s legs while waiting for medical personnel to arrive.
White House Press Secretary Karoline Leavitt later confirmed in a statement that the individual had fainted but was “okay.” She added, “During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted. The White House Medical Unit quickly jumped into action, and the gentleman is okay. The press conference will resume shortly.”
Read Also: United States: Hundreds Of Flights Canceled As Shutdown Stays
The event was convened to announce a major agreement with drug manufacturers Novo Nordisk and Eli Lilly to reduce prices for GLP-1 weight-loss and diabetes medications, including Ozempic, Wegovy, and Zepbound. Under the deal, the companies will expand access to these treatments through a new federal platform, TrumpRx, scheduled to launch next year.
According to administration officials, the oral versions of GLP-1 drugs will be priced as low as $149 per month once approved by the U.S. Food and Drug Administration. Injectable versions will cost $245 per month for Medicare and Medicaid patients using them for FDA-approved medical conditions such as diabetes.
Health Secretary Kennedy Jr. described the initiative as a step toward addressing health inequity. “Obesity is a disease of poverty,” he said. “These drugs have only been available to those with wealth. That ends now.”
Dr. Oz added that the deal could lead to what he called “a national health transformation,” predicting that Americans could collectively lose “135 billion pounds” within a year of the program’s launch.
The executive who fainted was treated on site and later confirmed to be in stable condition.
